✦ LIBER ✦

O-101 XYOTAX™/carboplatin vs paclitaxel/carboplatin for the treatmentof PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The stellar 3 phase III study

✍ Scribed by Langer, C.; O'Byrne, K.; Ross, H.; Socinski, M.; Szczesna, A.; Dediu, M.; Orlov, S.; Smakal, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1122 ORAL Paclitaxel poliglumex vs. gemc

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 149 KB

O-104 XYOTAXT™ vs. gemcitabine or vinore

✍ O'Brien, M.; Sandler, A.; Popovich, A.; Ganchev, H.; Bogdanova, N.; Miziara, J. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 143 KB

O-082 A randomized phase III trial compa

✍ Blumenschein, G.; Ludwig, C.; Thomas, G.; Tan, E.; Fanucchi, M.; Santoro, A.; Cr 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB

O-099 XYOTAX™ vs. docetaxel for the seco

✍ Bonomi, P.; Paz-Ares, L.; Langer, C.; O'Brien, M.; Gervais, R.; Gatzemeier, U.; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Phase II study of the proteasome inhibit

✍ Li, Tianhong; Ho, Liawaty; Piperdi, Bilal; Elrafei, Tarek; Camacho, Fernando J.; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 240 KB

Docetaxel + Cisplatin (DC) and Docetaxel

✍ F. Fossella 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 140 KB